Temporary importation of Iomeron® (iomeprol injection) to address drug shortage issues Due to a prior shortage of iodinated contrast media indicated for intravascular use in the U.S. market, Bracco Diagnostics Inc.

New Survey Finds 55% of Radiologists Have Concerns About Contrast Agent Availability Bracco Diagnostics Inc. releases data from 200 radiologists on the current state of their field

Bracco Announces the 2022 “Leaders on the Horizon” Residency Program Recipients Radiology residents receive scholarship, research publication in Applied Radiology supplement, and invite to RSNA reception.

Leaders on the Horizon The Bracco-Supported Applied Radiology Residency Program that champions the next generation of radiology leaders

Unique Device Identification To comply with the U.S. Food and Drug Administration ruling on Unique Device Identification (UDI) and improve supply chain efficiency, Bracco Diagnostics is transitioning to a GS1 compliant barcode.

Bracco joins the UN Global Compact The UN Global Compact is a call to companies everywhere to align their operations and strategies with ten universally accepted principles in the areas of human rights, labour, environment and anti-corruption.

The Impact of Seeing the Full Picture Bracco’s standpoint on sustainability - and environmental sustainability in particular - is that it is essential to look at the full picture.

Gadopiclenol This webpage on GADOPICLENOL provides an informative overview of the new FDA approved contrast-agent. This page is an informative and unbranded resource for anyone interested in learning more about GADOPICLENOL news and press releases.​

Bracco announces the birth of Bracco Japan Ltd Bracco will acquire all shares of Bracco-Eisai held by Eisai and change its name from Bracco-Eisai to Bracco Japan, Ltd.  as of April 1, 2023.

Patents